drugset / Trial / NCT01054313
Docetaxel and Sirolimus in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study to find the highest tolerated dose of the combination of Taxotere (docetaxel) and Rapamycin (sirolimus) when given to patients with advanced cancer. Researchers also want to find highest tolerated dose of the combination of docetaxel, sirolimus, and prednisone when given to patients with advanced prostate cancer. The safety of both drug combinations will also be studied.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Sirolimus | Small molecule | 1 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |
Indications
No indication recorded.